2026 Convergence Forum Fellows

This May Roivant Social Ventures hosted our third annual Convergence Forum Fellowships Program in support of CEOs championing healthcare equity through the development of therapeutics and technology.

We are excited to share that Roivant Social Ventures’ 2026 Convergence Fellows are:

• Daniel Mukasa, PhD, CEO of Ab Initio Bio. Ab Initio Bio is building foundation models for biomanufacturing, with the goal of compressing process development timelines and expanding access to biologic medicines.

• Mohan Purushothaman, PhD, CEO of Progentec Diagnostics, Inc., a digital health company specializing in autoimmune diseases, particularly lupus. Progentec aims to address the unique challenges faced by autoimmune patients, where 92% of their patients are women and 86% represent BIPOC communities. 

• Jo Varshney, PhD, CEO of VeriSIM Life. VeriSIM Life is focused on improving how therapeutics are developed to be both more predictive and more equitable, ensuring that decisions better reflect diverse, often underrepresented patient populations.

The Convergence Forum for Leaders in Healthcare Innovation is an invitation only annual event that explores what’s happening in the rapidly-converging worlds of biotech, pharma, healthcare, medical devices, and the Internet. The programs foster debate and discussion while providing an opportunity for participants to make important new contacts, explore new directions in research, and delve deeply into what it takes to maintain competitive advantage in a fast-changing world.